What is Zedsen?
Zedsen operates at the intersection of advanced electrical signal processing and oncology, dedicated to democratizing access to breast cancer diagnostics. By utilizing sophisticated AI/ML algorithms, the company provides a non-invasive, portable alternative to traditional screening methods. This technology is specifically engineered to assess breast density and cancer risk with high precision, effectively lowering the barrier to entry for early detection in GP and community clinic settings.
A core component of Zedsen's market position is its commitment to health equity. The company is actively addressing diagnostic disparities that disproportionately affect women of color and younger demographics. By delivering actionable clinical insights at a fraction of the cost of conventional imaging, Zedsen is effectively disrupting the traditional healthcare paradigm and establishing a new standard for accessible, preventative care.
How much funding has Zedsen raised?
Zedsen has raised a total of $12M across 1 funding round:
Series B
$12M
Series B (2021): $12M with participation from Bonnie Mcalveen Hunter, Joseph R. Grano, Nasser Kazeminy, Tony Rice, and Jim Harpel
Key Investors in Zedsen
Bonnie Mcalveen Hunter
A prominent private investor with a history of supporting high-impact healthcare and technology ventures.
Joseph R. Grano
An experienced investor focused on strategic growth opportunities within the medical and enterprise technology sectors.
Nasser Kazeminy
A seasoned investor known for backing innovative companies that aim to disrupt traditional industry paradigms.
What's next for Zedsen?
With the successful closure of this major strategic investment, Zedsen is poised to enter a phase of rapid commercial expansion and clinical validation. The company's roadmap likely involves scaling its manufacturing capabilities to meet the demand for portable diagnostic units while simultaneously refining its AI/ML models through broader clinical data sets. Strategic partnerships with primary care networks will be essential for the firm to achieve its goal of integrating its technology into routine health check-ups globally.
Furthermore, the organization is expected to focus on long-term sustainability by demonstrating the cost-effectiveness of its diagnostic solutions to healthcare providers and insurance payers. As Zedsen continues to push the boundaries of medical innovation, the focus will remain on maintaining high diagnostic accuracy while ensuring that their technology remains a scalable, user-friendly tool for clinicians worldwide.
